Stronghold Plus

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

selamectin, sarolaner

Available from:

Zoetis Belgium SA

ATC code:

QP54AA55

INN (International Name):

selamectin, sarolaner

Therapeutic group:

Mačke

Therapeutic area:

Antiparasitic izdelkov, insekticidi in repelenti, Macrocyclic laktonov, , kombinacije

Therapeutic indications:

Za mačke z ali brez nevarnosti mešanih parazitskih napadov s klopi in bolhami, uši, pršicami, gastrointestinalnimi ogorčicami ali srčnim črvom. Zdravilo za uporabo v veterinarski medicini je izključno označeno, kadar je uporaba proti klopom istočasno označena z enim ali več drugimi ciljnimi paraziti..

Product summary:

Revision: 4

Authorization status:

Pooblaščeni

Authorization date:

2017-02-08

Patient Information leaflet

                                19
B. NAVODILO ZA UPORABO
20
NAVODILO ZA UPORABO
STRONGHOLD PLUS 15 MG/2,5 MG KOŽNI NANOS, RAZTOPINA ZA MAČKE ≤ 2,5
KG
STRONGHOLD PLUS 30 MG/5 MG KOŽNI NANOS, RAZTOPINA ZA MAČKE > 2,5–5
KG
STRONGHOLD PLUS 60 MG/10 MG KOŽNI NANOS, RAZTOPINA ZA MAČKE > 5–10
KG
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVORNEGA ZA SPROŠČANJE SERIJ, ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom in proizvajalec odgovoren za
sproščanje serij:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIJA
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Stronghold Plus 15 mg/2,5 mg kožni nanos, raztopina za mačke ≤ 2,5
kg
Stronghold Plus 30 mg/5 mg kožni nanos, raztopina za mačke > 2,5–5
kg
Stronghold Plus 60 mg/10 mg kožni nanos, raztopina za mačke > 5–10
kg
selamektin/sarolaner
3.
NAVEDBA UČINKOVIN(E) IN DRUGE(IH) SESTAVIN
Vsak posamezni odmerek (merilna kapalka) vsebuje:
UČINKOVINA(E):
Stronghold Plus kožni nanos,
raztopina
Vsebina merilne
kapalke (ml)
selamektin (mg)
sarolaner (mg)
mačke ≤2,5 kg
0,25
15
2,5
mačke >2,5–5 kg
0,5
30
5
mačke >5–10 kg
1
60
10
POMOŽNE SNOVI:
0,2 mg/ml butilhidroksitoluena.
Kožni nanos, raztopina.
Prozorna, brezbarvna do rumena raztopina.
4.
INDIKACIJA(E)
Za mačke, ki imajo ali so izpostavljene mešanim parazitarnim
infestacijam/infekcijam s klopi,
bolhami, ušmi, garjami, gastrointestinalnimi nematodi ali srčno
glisto. To zdravilo je indicirano samo
takrat, ko je potrebna sočasna uporaba proti klopom in proti enemu
ali več drugim ciljnim parazitom.
EKTOPARAZITI:
-
Za zdravljenje in preprečevanje bolhavosti (C
_tenocephalides spp_
.). Zdravilo ima takojšen in
trajen ubijajoč učinek proti novim infestacijam, ki traja vsaj 5
tednov. Zdravilo 5 tednov ubija
odrasle bolhe, preden izležejo nova jajčeca. Zaradi svojega
ovicidnega in larvicidnega
21
delovanja zdravilo lahko pomaga pri kontroli infestacije z bolhami v
okolju, do katerega imajo
živali dostop.
-
To zdravilo lahko uporabimo kot del z
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Stronghold Plus 15 mg/2,5 mg kožni nanos, raztopina za mačke ≤ 2,5
kg
Stronghold Plus 30 mg/5 mg kožni nanos, raztopina za mačke > 2,5–5
kg
Stronghold Plus 60 mg/10 mg kožni nanos, raztopina za mačke > 5–10
kg
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Vsak posamezni odmerek (merilna kapalka) vsebuje:
UČINKOVINA(E):
Stronghold Plus kožni nanos,
raztopina
Vsebina merilne
kapalke (ml)
selamektin (mg)
sarolaner (mg)
mačke ≤2,5 kg
0,25
15
2,5
mačke >2,5–5 kg
0,5
30
5
mačke >5–10 kg
1
60
10
POMOŽNE SNOVI:
0,2 mg/ml butilhidroksitoluena.
Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Kožni nanos, raztopina.
Prozorna, brezbarvna do rumena raztopina.
4.
KLINIČNI PODATKI
4.1
CILJNA ŽIVALSKA VRSTA
Mačke.
4.2
INDIKACIJE ZA UPORABO PRI CILJNIH ŽIVALSKIH VRSTAH
Za mačke, ki imajo ali so izpostavljene mešanim parazitarnim
infestacijam/infekcijam s klopi,
bolhami, ušmi, garjami, gastrointestinalnimi nematodi ali srčno
glisto. To zdravilo je indicirano samo
takrat, ko je potrebna sočasna uporaba proti klopom in proti enemu
ali več drugim ciljnim parazitom.
EKTOPARAZITI:
-
Za zdravljenje in preprečevanje bolhavosti (C
_tenocephalides spp_
.). Zdravilo ima takojšen in
trajen ubijajoč učinek proti novim infestacijam, ki traja vsaj 5
tednov. Zdravilo 5 tednov ubija
odrasle bolhe, preden izležejo nova jajčeca. Zaradi svojega
ovicidnega in larvicidnega delovanja
zdravilo lahko pomaga pri kontroli infestacije z bolhami v okolju, do
katerega imajo živali
dostop.
-
To zdravilo lahko uporabimo kot del zdravljenja pri z bolhami
pogojenem alergijskem
dermatitisu (FAD)..
-
Zdravljenje infestacij s klopi. To zdravilo ima takojšen in trajen
učinek ubijanja klopov vrste
_Ixodes ricinus _
in
_Ixodes hexagonus_
, ki traja 5 tednov, za klope vrste
_Dermacentor reticulatus _
in
_ _
_Rhipicephalus sanguineus _
pa učinek traja 4 tedne.
-
Zdravljenje ušesnih garij (
_Otodectes c
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 20-12-2021
Public Assessment Report Public Assessment Report Bulgarian 09-03-2017
Patient Information leaflet Patient Information leaflet Spanish 20-12-2021
Public Assessment Report Public Assessment Report Spanish 09-03-2017
Patient Information leaflet Patient Information leaflet Czech 20-12-2021
Public Assessment Report Public Assessment Report Czech 09-03-2017
Patient Information leaflet Patient Information leaflet Danish 20-12-2021
Public Assessment Report Public Assessment Report Danish 09-03-2017
Patient Information leaflet Patient Information leaflet German 20-12-2021
Public Assessment Report Public Assessment Report German 09-03-2017
Patient Information leaflet Patient Information leaflet Estonian 20-12-2021
Public Assessment Report Public Assessment Report Estonian 09-03-2017
Patient Information leaflet Patient Information leaflet Greek 20-12-2021
Public Assessment Report Public Assessment Report Greek 09-03-2017
Patient Information leaflet Patient Information leaflet English 20-12-2021
Public Assessment Report Public Assessment Report English 09-03-2017
Patient Information leaflet Patient Information leaflet French 20-12-2021
Public Assessment Report Public Assessment Report French 09-03-2017
Patient Information leaflet Patient Information leaflet Italian 20-12-2021
Public Assessment Report Public Assessment Report Italian 09-03-2017
Patient Information leaflet Patient Information leaflet Latvian 20-12-2021
Public Assessment Report Public Assessment Report Latvian 09-03-2017
Patient Information leaflet Patient Information leaflet Lithuanian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 20-12-2021
Public Assessment Report Public Assessment Report Lithuanian 09-03-2017
Patient Information leaflet Patient Information leaflet Hungarian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 20-12-2021
Public Assessment Report Public Assessment Report Hungarian 09-03-2017
Patient Information leaflet Patient Information leaflet Maltese 20-12-2021
Public Assessment Report Public Assessment Report Maltese 09-03-2017
Patient Information leaflet Patient Information leaflet Dutch 20-12-2021
Public Assessment Report Public Assessment Report Dutch 09-03-2017
Patient Information leaflet Patient Information leaflet Polish 20-12-2021
Public Assessment Report Public Assessment Report Polish 09-03-2017
Patient Information leaflet Patient Information leaflet Portuguese 20-12-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 20-12-2021
Public Assessment Report Public Assessment Report Portuguese 09-03-2017
Patient Information leaflet Patient Information leaflet Romanian 20-12-2021
Public Assessment Report Public Assessment Report Romanian 09-03-2017
Patient Information leaflet Patient Information leaflet Slovak 20-12-2021
Public Assessment Report Public Assessment Report Slovak 09-03-2017
Patient Information leaflet Patient Information leaflet Finnish 20-12-2021
Public Assessment Report Public Assessment Report Finnish 09-03-2017
Patient Information leaflet Patient Information leaflet Swedish 20-12-2021
Public Assessment Report Public Assessment Report Swedish 09-03-2017
Patient Information leaflet Patient Information leaflet Norwegian 20-12-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 20-12-2021
Patient Information leaflet Patient Information leaflet Icelandic 20-12-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 20-12-2021
Patient Information leaflet Patient Information leaflet Croatian 20-12-2021
Public Assessment Report Public Assessment Report Croatian 09-03-2017

Search alerts related to this product